ESMC
Escalon Medical Corp.0.1400
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.04MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
10-K
FY2025 results
Escalon Medical eked out a slim FY2025 profit of $105,525 on $12.0M revenue, up 0.5% y/y, with Trek products driving the gain while Sonomed and AXIS dipped slightly; gross margins expanded to 54.3% from 57.0% via product mix shifts, though R&D climbed 9.4% on AXIS consulting. Q4 momentum stayed steady, flipping from FY2024's $125K loss amid positive operating cash flow of $381K—yet inventory swelled $486K, signaling caution. Debt ticked down to $523K with $40K repayments, but liquidity strains persist alongside tariff uncertainties. Going concern doubts loom large.
10-Q
Q3 FY2025 results
Escalon Medical Corp. swung to profitability in Q3 FY2025 ended March 31, 2025, with net revenues climbing 28.9% y/y to $3.5M, driven by stronger sales of Sonomed's ultrasound products and Trek's gas products, while gross margin expanded to 46.1% from 41.4% on favorable product mix and geographic shifts. For the nine-month YTD, revenues rose 11.4% y/y to $9.5M, yielding operating income of $505K versus a $243K loss last year, and net income of $485K; diluted EPS held at $0.03 on 14.2M shares, reflecting preferred stock conversion effects with no anti-dilution from options. Cash swelled to $541K from $209K at FY start, bolstered by $365K operating cash flow—exceeding capex of zero for positive FCF—while total debt eased to $516K including a $133K TD note at 9.49% maturing 2028 and $143K EIDL at 3.75% over 30 years, with no revolver. Domestic sales edged to 55% of total, up from 52%, yet one customer tied to 16% of YTD revenue underscores concentration risks.
8-K
Auditor switch announced
Escalon Medical Corp. switched auditors on April 2, 2025, after Marcum LLP resigned due to its attest business acquisition by CBIZ CPAs P.C., which the company promptly engaged with Audit Committee approval. Marcum's prior reports were clean except for a going concern note, with no disagreements but ongoing material weaknesses in inventory valuation controls. This transition ensures audit continuity. Weaknesses persist.
10-Q
Q2 FY2025 results
Escalon Medical Corp. posted solid Q2 FY2025 results, with net revenues climbing 12.3% y/y to $3.2M, driven by stronger Trek gas and Sonomed ultrasound sales, while YTD revenues edged up 3.2% y/y to $6.0M despite softer service plans. Gross margins expanded to 51.1% from 56.0% y/y, thanks to favorable product mix and pricing tweaks, flipping operations to a $256K profit versus last year's $71K loss; net income hit $246K, or $0.02 diluted EPS on 14.1M shares (anti-dilution from preferred conversion). Cash swelled to $521K, with $334K operating cash flow (derived) fueling repayments on the $142K TD note (9.49% fixed) and $144K EIDL loan (3.75%). Working capital strengthened to $2.1M. Foreign sales held steady at 47% of revenue. Yet regulatory hurdles from FDA inspections loom large.
IPO
Employees
Sector
Industry
APYX
Apyx Medical Corporation
3.72-0.07
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
EW
Edwards Lifesciences Corporatio
85.32+1.94
GKOS
Glaukos Corporation
113.76+2.03
IRIX
IRIDEX Corporation
1.00+0.02
MASI
Masimo Corporation
134.52-2.88
RMD
ResMed Inc.
247.34-5.73
SGHT
Sight Sciences, Inc.
8.39+0.08
VYCO
Vycor Medical, Inc.
0.16+0.00